Single-cell RNA Sequencing (scRNA-seq): Advances and Challenges for Cardiovascular Diseases (CVDs). 2024

Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City and Southwest University, College of Agronomy and Biotechnology, Southwest University, Chongqing, 400715, China; Engineering Research Center of South Upland Agriculture, Ministry of Education, Chongqing, 400715, China; Women Medical and Dental College, Khyber Medical University, Peshawar, KPK, 22020, Pakistan.

Implementing Single-cell RNA sequencing (scRNA-seq) has significantly enhanced our comprehension of cardiovascular diseases (CVDs), providing new opportunities to strengthen the prevention of CVDs progression. Cardiovascular diseases continue to be the primary cause of death worldwide. Improving treatment strategies and patient risk assessment requires a deeper understanding of the fundamental mechanisms underlying these disorders. The advanced and widespread use of Single-cell RNA sequencing enables a comprehensive investigation of the complex cellular makeup of the heart, surpassing essential descriptive aspects. This enhances our understanding of disease causes and directs functional research. The significant advancement in understanding cellular phenotypes has enhanced the study of fundamental cardiovascular science. scRNA-seq enables the identification of discrete cellular subgroups, unveiling previously unknown cell types in the heart and vascular systems that may have relevance to different disease pathologies. Moreover, scRNA-seq has revealed significant heterogeneity in phenotypes among distinct cell subtypes. Finally, we will examine current and upcoming scRNA-seq studies about various aspects of the cardiovascular system, assessing their potential impact on our understanding of the cardiovascular system and offering insight into how these technologies may revolutionise the diagnosis and treatment of cardiac conditions.

UI MeSH Term Description Entries
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000092386 Single-Cell Gene Expression Analysis Assaying the products of GENETIC TRANSCRIPTION in individual cells. Sc-RNAseq,ScRNA-seq,ScRNAseq,Single Cell Gene Expression Analysis,Single Cell Gene Expression Profiling,Single Cell Transcriptome Analysis,Single-Cell Gene Expression Profiling,Single-Cell RNA Seq,Single-Cell RNA-Seq,Single-Cell RNAseq,Single-Cell Transcriptome Analysis,Analyses, Single-Cell Transcriptome,Analysis, Single-Cell Transcriptome,RNA Seq, Single-Cell,RNA-Seq, Single-Cell,RNAseq, Single-Cell,Sc RNAseq,ScRNA seq,Seq, Single-Cell RNA,Seqs, Single-Cell RNA,Single Cell RNA Seq,Single Cell RNAseq,Single-Cell Transcriptome Analyses,Transcriptome Analyses, Single-Cell,Transcriptome Analysis, Single-Cell
D017423 Sequence Analysis, RNA A multistage process that includes cloning, physical mapping, subcloning, sequencing, and information analysis of an RNA SEQUENCE. RNA Sequence Analysis,Sequence Determination, RNA,Analysis, RNA Sequence,Determination, RNA Sequence,Determinations, RNA Sequence,RNA Sequence Determination,RNA Sequence Determinations,RNA Sequencing,Sequence Determinations, RNA,Analyses, RNA Sequence,RNA Sequence Analyses,Sequence Analyses, RNA,Sequencing, RNA
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
August 2014, Nucleic acids research,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
January 2021, Vascular health and risk management,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
September 2021, Experimental eye research,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
January 2023, Methods in molecular biology (Clifton, N.J.),
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
October 2020, Current opinion in microbiology,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
January 2024, Functional & integrative genomics,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
October 2018, Nature protocols,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
June 2021, Molecular therapy oncolytics,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
April 2024, Functional & integrative genomics,
Shahid Ullah Khan, and Yuqing Huang, and Hamid Ali, and Ijaz Ali, and Saleem Ahmad, and Safir Ullah Khan, and Talib Hussain, and Muneeb Ullah, and Kun Lu
January 2019, Methods in molecular biology (Clifton, N.J.),
Copied contents to your clipboard!